Norges Bank Investment Management added four prominent traditional Chinese medicine (TCM) firms to its exclusion list but has also been increasing its emerging market exposure.
Investors still favour private equity assets for their higher growth, better governance structures, and diversification potential.
With social equality and national security being the main drivers for further regulations, investors are keeping a wary eye on the next possible targets.
The healthcare industry in China is propelled by significant reforms and presents exciting investment opportunities. However, the returns it delivers are volatile. How should investors navigate this market?
Economic developments in Asia present investment opportunities and current high valuations may be "an accident waiting to happen", say investors.
Healthcare and technology start-ups remain hot property, but pandemic-fuelled uncertainty has led to lower valuations in some areas, such as travel-related platforms.